干预治疗药物，了解 2 型糖尿病缓解途径：第 2 部分。
Intervention with Therapeutic Agents, Understanding the Path to Remission to Type 2 Diabetes: Part 2.
机构信息
Division of Pediatric Endocrinology, Children's Healthcare of Atlanta, Emory University School of Medicine, 1400 Tullie Road Northeast, Atlanta, GA 30329, USA.
Division of Endocrinology, Metabolism & Lipids, Emory University School of Medicine, 69 Jesse Hill Jr Drive Southeast, Glenn Building, Atlanta, GA 30303, USA.
出版信息
Endocrinol Metab Clin North Am. 2023 Mar;52(1):39-47. doi: 10.1016/j.ecl.2022.07.004. Epub 2022 Nov 18.
Type 2 diabetes is characterized by progressive decline in pancreatic β-cell function. Newer agents, such as glucagon-like peptide-1 receptor agonist (GLP-1RA) and dual incretin agonists, can augment β-cell function and delay the need for additional antihyperglycemics. However, the effect on β-cell function ceases after stopping the medications. When combined with intensive lifestyle modifications, higher doses of GLP-1RA than those used for diabetes treatment can be used to induce weight loss. More research is needed on whether the weight loss achieved with GLP1-RA can be sustained after stopping medication and in turn can sustain diabetes remission.
2 型糖尿病的特征是胰腺β细胞功能进行性下降。新型药物，如胰高血糖素样肽-1 受体激动剂（GLP-1RA）和双重肠促胰岛素激动剂，可以增强β细胞功能，并延缓对其他抗高血糖药物的需求。然而，停止药物治疗后，这种作用就会停止。当与强化生活方式改变相结合时，GLP-1RA 的剂量可以高于治疗糖尿病的剂量，以诱导体重减轻。需要更多的研究来确定 GLP1-RA 治疗后体重减轻是否可以持续，以及是否可以维持糖尿病缓解。
Zotero 插件